Trial reportNature medicine2005
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.
Trial report in Nature medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03823365 (Immune Reconstitution With Blinatumomab Expanded T-cells), which is not on this map. Cited by 147 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immune Reconstitution With Blinatumomab Expanded T-cells (BET) After First-line Treatment With Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab in CD20+ Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia: a Phase I Study
Who cites it
147 citing papers in PubMed, 1 synthesis or guideline pooled it, 288 citations in OpenAlex.
- Comparative efficacy of glioma treatment strategies: an umbrella review of meta-analyses.Annals of medicine · 2025Pooled it
- Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Trial
- Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.JCI insight · 2018Trial
- Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Trial
- Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Trial
- Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.British journal of haematology · 2012Trial
- CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.Science translational medicine · 2012Trial
- Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.Cancer immunology, immunotherapy : CII · 2012Trial
- Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Trial
- T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.Science translational medicine · 2011Trial
- Trial
- Trial
- Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Trial
- Engineering mRNA CAR-T Cells for Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2025Article
- CARNature communications · 2023Article
- Highlights into historical and current immune interventions for cancer.International immunopharmacology · 2023Review
- It takes T to tango: immunotherapy in MM.Blood · 2022Article
87 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
32 authors at 5 institutions in 1 country.
Funding
Abstract
Immunodeficiency is a barrier to successful vaccination in individuals with cancer and chronic infection. We performed a randomized phase 1/2 study in lymphopenic individuals after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for myeloma. Combination immunotherapy consisting of a single early post-transplant infusion of in vivo vaccine-primed and ex vivo costimulated autologous T cells followed by post-transplant booster immunizations improved the severe immunodeficiency associated with high-dose chemotherapy and led to the induction of clinically relevant immunity in adults within a month after transplantation. Immune assays showed accelerated restoration of CD4 T-cell numbers and function. Early T-cell infusions also resulted in significantly improved T-cell proliferation in response to antigens that were not contained in the vaccine, as assessed by responses to staphylococcal enterotoxin B and cytomegalovirus antigens (P < 0.05). In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the development of enhanced memory T-cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.